Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Venezuelan equine encephalitis virus envelope glycoprotein E2 is a structural component of the viral envelope, forming heterodimers with E1 that assemble into trimeric spikes on the virion surface. Derived from cleavage of the pE2 precursor (which includes E3), E2 mediates host receptor binding for viral entry, including interactions with LDLRAD3, heparan sulfate, and other receptors, and interacts with the capsid protein during assembly and maturation. It features domains A (receptor binding), B (protects E1 fusion loop), C (host recognition), and a β-ribbon connector, with its C-terminal tail anchoring to the viral membrane and binding capsid.
Inhibits viral attachment to host cells; Blocks viral egress; Prevents viral fusion; Competes for receptor binding (e.g., LDLRAD3)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Venezuelan equine encephalitis virus envelope glycoprotein E2 (E2).